Arbutus Biopharma (ABUS) announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical. The parties have mutually agreed to conclude the strategic partnership entered into in 2021 for development, manufacturing and commercialization of imdusiran in mainland China, Hong Kong, Macau and Taiwan markets. Arbutus has also launched a new Scientific Advisory Board, SAB, which will include: Jordan Feld, Edward Gane, Anna Suk-Fong Lok, Mark Sulkowski, and Man-Fung Yuen.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Arbutus Biopharma Holds Annual Shareholder Meeting
- Mount Logan Capital Reports Q1 2025 Financial Results
- Arbutus Biopharma Achieves Milestones in Hepatitis B Treatment and Expands Leadership
- Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)
- Arbutus Biopharma Unveils Promising HBV Treatment Data